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Background: Boron neutron capture therapy (BNCT) is a selective radiotherapy that is dependent on the
accumulation of 10B compound in tumors. Low-intensity ultrasound produces a transient pore on cell membranes,
sonoporation, which enables extracellular materials to enter cells. The effect of sonoporation on BNCT was
examined in oral squamous cell carcinoma (SCC) xenografts in nude mice.
Materials and methods: Tumor-bearing mice were administrated boronophenylalanine (BPA) or boronocaptate
sodium (BSH) intraperitoneally. Two hours later, tumors were subjected to sonoporation using microbubbles
followed by neutron irradiation.
Results: The 10B concentration was higher in tumors treated with sonoporation than in untreated tumors, although
the difference was not significant in BPA. When tumors in mice that received BPA intraperitoneally were treated
with sonoporation followed by exposure to thermal neutrons, tumor volume was markedly reduced and the
survival rate was prolonged. Such enhancements by sonoporation were not observed in mice treated with
BSH-mediated BNCT.
Conclusions: These results indicate that sonoporation enhances the efficiency of BPA-mediated BNCT for oral SCC.
Sonoporation may modulate the microlocalization of BPA and BSH in tumors and increase their intracellular levels.
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Head and neck cancer, mostly of squamous-cell origin,
account for 6.5% of all tumors [1]. The standard treat-
ment for patients with head and neck cancer includes
chemotherapeutic drugs, surgery, and radiotherapy [2].
However, the 5-year survival rate of these patients has
remained in the range of 50-60% for the last three decades
[3]. Radiotherapy plays a key role in the management of
locally advanced stages; however, its results remain rela-
tively poor in advanced cases. Several approaches have
been developed to improve its efficacy, while maintaining
acceptable toxicities.* Correspondence: yura@dent.osaka-u.ac.jp
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distribution, and reproduction in any mediumBoron neutron capture therapy (BNCT) is a binary
treatment modality for cancer involving the accumula-
tion of agents containing the isotope 10B in cancer cells
followed by irradiation with thermal neutrons [4,5].
Capture of a thermal neutron by the 10B nucleus initi-
ates a nuclear reaction in which the decay of an excited
10 nucleus produces a high linear energy transfer of
alpha-particles and lithium nucleus. These particles
have short path lengths of 5-10 μm in water. Side
effects typically associated with ionizing radiation can
be avoided, if 10B agents can be selectively targeted to
tumor cells.
Ultrasound-assisted gene delivery has recently been
developed as an alternative to a non-viral approach [6,7].
The process referred to as sonoporation is a physical
method using an external ultrasound energy source to
induce DNA to enter the cell [8,9]. Sonoporation istral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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microbubbles, originally developed as ultrasound contrast
agents for medical imaging [10,11]. Promising results have
been reported using sonoporation for gene transfer in
various animal tissues and tumor models [10,12-14]. How-
ever, the effect of sonoporation on BNCT has not yet been
studied. In the present study, we examined whether sono-
poration with microbubbles could enhance the antitumor
effect of BPA- or BSH-mediated BNCT on human oral
squamous cell carcinoma (SCC) xenografts in nude mice.
Materials and methods
Cells and tumors
The human oral SCC cell line SAS was obtained from the
Japanese Collection of Research Bioresources (Tokyo,
Japan). To generate tumors in nude mice, 1 × 106 cells
were inoculated subcutaneously into the back of the leg of
5-week-old female Balb/c nude mice (Clea Japan Inc.,
Japan). Animals were used for BNCT experiments when
the tumors reached a suitable size, i.e., approximately
5 mm in diameter.
Sonoporation
SonoVue (Bracco Diagnostic, Princeton, NJ), a lipid-shelled
ultrasound contrast agent filled with perfluorocarbon
gas [15,16], is composed of 5 × 108 microbubbles/ml,
having an average diameter of 2.5 μm. Microbubbles
were used at a dose of 5 × 107 /100 μl. An ultrasound
machine, Sonitron 2000 V (NEPAGENE Japan, Chiba,
Japan), was used for ultrasound exposure and the head
of the transducer, 12 mm in diameter, was placed on the
skin through an ultrasound contact gel. The ultrasound
frequency was 1 MHz throughout the experiments.
Ultrasound was adjusted to supply an intensity of
0.5 W/cm2 at a duty cycle of 20% for 10 sec, referring to
the results of a previous study [17]. To determine the
effect of sonoporation (ultrasound in the presence of
microbubbles), tumors in nude mice received microbub-
bles and then were exposed to ultrasound. Control tumors
were left untreated. Tumor length (L) and width (W)
were measured every 3-4 days. Tumor volume (V) was
determined by the formula: V = LW2/2.
To determine the effect of sonoporation with micro-
bubbles on the growth of nude mouse tumor, three
tumors in nude mice received microbubbles followed
by exposure to ultrasound. They were then followed
for 14 days and the tumor size was measured and volume
was calculated.
Boron compounds
10B-enriched ( >98%) BPA was obtained from Boron
Biologicals, Inc., (Raleigh, NC, USA) and converted to
a fructose complex following the method by Coderre et al
[18]. The aqueous solution of BPA was prepared at aconcentration of 250 mg/ml (21.28 mg 10B/ml). BSH
(Boron Biologicals) was dissolved in physiological saline.
To evaluate their concentrations in tumors, BPA and BSH
were injected intarperitoneally at a dose of 250 mg/kg
and 75 mg/kg, respectively. For the measurement of 10B
concentrations, tumors were excised immediately after
sonoporation and tumor tissues were dissolved in 0.95 M
ammonium sulfate and diluted by 10 volumes of water.
The 10B concentration in the sample was measured by
inductively coupled plasma-mass spectrometry (ICP-MS)
Agilent 7700 (Agilent Technologies, Palo Alto, CA,
USA). Three to four samples were used to determine
the concentrations of 10B and the mean values were
determined.
BNCT for oral SCC xenografts in nude mice
Tumor-bearing animals were given an intraperitoneal
injection of BPA or BSH. Two hours later, tumors were
subjected to sonoporation followed by neutron irradiation.
Control tumors were left untreated. Neutron irradiation
was delivered via a neutron beam at 1 MW (thermal neu-
tron mode 00-0011) in the Kyoto University Research
Reactor (KUR). The mouse was held stationary during
the irradiation for 120 min in a custom-designed acrylic
resin box from which the tumor-bearing legs were pulled
out through a narrow slit and fixed with adhesive. A LiF
thermoplastic plate with a hole that defined the irradiation
field was placed on the animal to expose the tumor-
bearing leg only to the neutron beam. Neutron fluence
was measured from the radioactivation of gold foil (3 mm
in diameter, 0.05 mm thick) placed at the front and back
of the tumors [19]. The average fluence of the thermal
neutron was 4.72 × 1012 n/cm2 at 1 MW. Thermolumines-
cent dosimeters were used for gamma-ray dosimetry, and
the total gamma ray dose was 3.95 Gy after irradiation
for 120 min. Thermal neutron fluence was converted to a
physical dose using the equation D =Φ{(7.43 × 10− 14)B +
(6.782 × 10− 14)N} + G.
Where D = physical dose, Φ = neutron fluence (n/cm2),
B = boron concentration (ppm), N = nitrogen concentra-
tion (2%), and G = gamma-ray dose (Gy). The 10B con-
centrations were measured twice and the mean values
were obtained. The experiments for antitumor effect on
BNCT were started at the time of neutron irradiation.
Experimental groups included untreated control, neu-
tron only, BPA-mediated BNCT, BPA-mediated BNCT
in combination with sonoporation, BSH-mediated BNCT,
and BSH-mediated BNCT in combination with sonopora-
tion groups. In the case of BNCT in combination with
sonoporation, neutron irradiation was started immediately
after sonoporation. Four tumors in each group were
used in an experiment. Repeated data were combined to
evaluate tumor volume and survival rate. Experiments
using nude mice were performed with the approval of
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Histological examination
Tumors were treated by BNCT in combination with
sonoporation and subjected to histological examination
24 h later. Tumor tissues fixed in 10% formalin were
embedded in paraffin. Sections were deparaffinized,
rehydrated, and stained with hematoxylin and eosin (H-E).
Statistical analysis
All values were expressed as the mean ± SD. A repeated
measure ANOVA test was used to determine the signifi-
cance of differences in tumor volume. After confirming
significant differences, the mean tumor volume in each
group was analyzed with the unpaired Student’s t test. The
survival time of animals was converted to Kaplan-Meier
plots, and the significance of the difference in survival
was calculated using the generalized Log-rank test.
These statistical analyses were performed using the soft-
ware Statcel2, version 2 (OMS, Tokyo, Japan). A value
of P < 0.05 was considered to be significant.
Results
Incorporation of 10B into oral SCC xenografts in nude
mice
In previous studies, the 10B concentration of tumors
reached a maximal level 2 h following the intraperitoneal
injection of BPA [20]. Tumor-bearing mice were also
intraperitoneally administered BPA or BSH and tumors
were removed 2 h later to measure concentrations of
10B. In the sonoporation groups, tumors received micro-
bubbles, and were then exposed to ultrasound prior to
sampling for the measurement of intratumoral 10B con-
centrations. When tumors that received intraperitoneal
injection of BPA were subjected to sonoporation, the
10B concentration was increased from 16.82 ± 6.23 to
22.72 ± 7.71 ppm. In BSH-injected animals, the 10B con-
centration in tumors was increased from 3.18 ± 1.09 to
9.84 ± 7.53 ppm by sonoporation (Table 1). Using 10B
concentrations in the tumors, the physical doses in the
BPA-mediated BNCT and BPA-mediated BNCT inTable 1 Physical doses for nude mouse tumors
Group 10B concentration (ppm) Physical dose (Gy)
N 0 4.59
BPA + N 16.82 ± 6.23 10.49 ± 2.18
BPA + S + N 22.72 ± 7.71 12.55 ± 2.70
BSH + N 3.18 ± 1.09 5.70 ± 0.38
BSH + S + N 9.84 ± 7.53* 8.04 ± 2.64*
N, neutron irradiation; BPA, Intraperitoneal injection of BPA; S, Sonoporation
(ultrasound irradiation in the presence of microbubbles); BSH, Intraperitoneal
injection of BSH. Values except for N were means ± SD of three to four
determinations. *P < 0.05 vs. BSH + N.combination with sonoporation groups were calculated as
10.49 ± 2.18 and 12.55 ± 2.70 Gy, respectively. Physical
doses in the BSH-mediated BNCT and BSH-mediated
BNCT in combination with sonoporation groups were
5.70 ± 0.38 and 8.04 ± 2.64 Gy, respectively (Table 1). In
both boron concentration and physical doses, there was a
significant difference (P < 0.05) between BSH groups
with or without sonoporation, but such difference was
not observed in BPA.
Effect of sonoporation on tumor volume
Whether sonoporation with microbubbles could affect the
growth of nude mouse tumor was examined. Tumors re-
ceived microbubbles followed by exposure to ultrasound.
Fourteen days later, the tumor volume was increased from
242 ± 96 mm3 to 1286 ± 557 mm3 and was 5.3-fold higher
than that of the initial volume, while tumor volume in the
control was 252 ± 87 mm3 to 1359 ± 380 mm3 and the in-
crease was 5.4-fold. No significant difference was observed
between the groups treated with sonoporation or controls,
which indicated that ultrasound with microbubbles did
not inhibit the growth of tumors.
Effect of BNCT in combination with sonoporation on
tumor volume
Tumor-bearing animals were administered BPA or BSH
intraperitoneally. Two hours later, tumors were treated
with BNCT in combination with sonoporation or without.
The experimental groups were as follows: untreated con-
trol, neutron only, BPA-mediated BNCT, BPA-mediated
BNCT in combination with sonoporation, BSH-mediated
BNCT, and BSH-mediated BNCT in combination with
sonoporation. In control animals, tumors continued to
grow and were 2354 ± 551 mm3 28 days after the start of
the experiment (Figure 1). A significant difference was ob-
served between the BPA-mediated BNCT and neutron
only groups 28 days after BNCT (P < 0.05). When tumors
were subjected to BPA-mediated BNCT in combination
with sonoporation, tumor volume was markedly decreased
from 4 days after neutron irradiation and most tumors
became undetectable at 8 days. A significant decrease
was observed between the BPA-mediated BNCT and
BPA-mediated BNCT in combination with sonopora-
tion groups 28 days after BNCT (p < 0.01). In the BSH-
mediated BNCT group, sonoporation did not alter the
effect of BNCT on tumor volume (Figure 1).
All untreated control animals died within 60 days of the
start of the experiment. Animals exposed to neutron only,
BSH-mediated BNCT, BSH-mediated BNCT in combin-
ation with sonoporation, and BPA-mediated BNCT died
by day 96, 79, 62, and 109, respectively. However, animals
whose tumors were treated with BPA-mediated BNCT in
combination with sonoporation survived longer than
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Figure 1 Effect of BNCT in combination with sonoporation on tumor volume. Nude mice carrying SAS tumors received BPA or BSH
intraperitoneally. Two hours later, tumors were treated with sonoporation followed by neutron exposure. The experimental groups were as follows:
untreated control (C), neutron only (N), BPA-mediated BNCT (BPA + N), BPA-mediated BNCT in combination with sonoporation (BPA + S + N),
BSH-mediated BNCT (BSH + N), and BSH-mediated BNCT in combination with sonoporation (BSH + S + N). After BNCT, tumor size was
measured during the experiment and tumor volume was determined. Four tumors in each group were used in an experiment. Repeated data
were combined to evaluate tumor volume and survival rate. Data were means ± SD.
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ent from that of mice treated with BPA-mediated BNCT
in combination with sonoporation (P < 0.05).
The skin on tumors had a normal appearance during
the experiment following BPA-mediated BNCT in com-
bination with sonoporation (Figure 3). No ulceration was
observed in any experimental animal, until the extensive
growth of tumors and necrotic changes occurred.
Histological examination of BNCT-treated tumors
BNCT-treated and untreated tumors were subjected to
histological examination. In control tumors, polyhedral
cells had intimate interactions each other, forming a solid
mass (Figure 4A), and were separated from the covering
skin epidermis by connective tissue. When tumors were
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Figure 2 Effect of BNCT in combination with sonoporation on the sur
as described in Figure 1. After the treatment, animals were observed and tsonoporation and were observed 24 h later, tumor nests
became unclear. Vacuolation of the cytoplasm, fragmen-
tation of nuclei and multinuclear cells were observed
(Figure 4B). The structure of the covering skin was pre-
served and the degradation of basal cells was not observed
(Figure 4C, D).Discussion
Since BPA is an analog of phenylalanine, its uptake has
been associated with amino acid synthesis in cells and
the cell cycle [21-23]. The uptake of BPA has also been
shown to be dependent on amino acid transporters such
as L-type amino acid transporter 1 (LAT-1) and LAT-4
[24,25]. LAT-negative cells may survive BNCT and








vival rates of animals. Nude mice carrying SAS tumors were treated
heir survival rates were measured.
Figure 3 Macroscopic observation of tumors treated with BNCT. (A) SAS cells were inoculated into the leg of nude mouse subcutaneously
and tumors were produced in 7 days. (B) When treated with BPA-mediated BNCT in combination with sonoporation after the intraperitoneal
injection of BPA, tumors became undetectable 18 days later. The experiments for antitumor effect on BNCT were started at the time of neutron
irradiation. (C) Untreated tumors 18 days from the start of the experiment showed extensive growth.
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intracellular 10B concentrations are required.
Electroporation is one of the methods used to increase
the delivery of exogenous molecules into cells and has
been shown to be effective in the introduction of drugs,
DNA, proteins, dyes, and other molecules into cells both
in vitro and in vivo [26]. The application of electric
pulses increased and prolonged the entrapment of BSH
in B16F1 melanoma tumors [27]. However, it requires
invasive needle electrode placement into the target tissue
to deliver electric pulses. Skin abrasion may be a compli-
cation of this procedure. Sonoporation with low intensity
ultrasound is another technique used to stimulate cell
membrane permeabilization and allow the incorporation
of extracellular materials. It offers advantages over electro-
poration, primarily as a result of its relatively non-invasive
nature [14]. The intensity of ultrasound is within the range
of 0.5 to 3 W/cm2 and is appropriate for medical applica-
tions. In the presence of microbubbles, its efficiency on
permeability of the cell membrane was shown to markedly
increase [11]. Accordingly, an enhancement in the antitu-
mor effect of chemotherapeutic agents and the delivery of
plasmid DNA in vitro and in vivo can be achieved [12-14].
Li et al. [13] infected human retinal pigmented epithelial
cells with adeno-associated virus under the following
ultrasound conditions: 1.0 W/cm2, a duty cycle of 20%,
and an exposure period of 20 sec, and found an increasein the green fluorescent protein-positive rate from 17 to
32%. No damage to cultured cells was observed under our
ultrasound conditions of an intensity of 1 W/cm2 and 20%
duty cycle for 10 sec [17]. The combination of ultrasound
with microbubbles did not inhibit the growth pattern of
oral SCC xenografts. Thus, it is unlikely that sonoporation
affects the growth of tumors.
We previously reported that the 10B concentration in
tumors peaked at approximately 2 h after an intraperi-
toneal injection of BPA, while BSH did not show a
time-dependent increase in 10B concentrations in tumors
[20]. In the present study, we performed sonoporation on
tumors 2 h after the intraperitoneal administration of
BPA, and found that the 10B concentration in tumors was
slightly increased. The highest concentration was obtained
in the BPA-mediated BNCT group. The effect of sono-
poration on 10B concentration was more prominent in
BSH-administered animals than in BPA-administered
animals, although the basal level of BSH was low. It is
likely that sonoporation can enhance the concentrations
of BPA and BSH in nude mouse tumors and also the
physical doses by neutron irradiation, although the
effect on BPA is not remarkable.
Consistent with the results of 10B concentrations
achieved in tumors, tumor growth was suppressed more
by BPA-mediated BNCT than neutrons only, however,
complete remission was not achieved at this physical




Figure 4 Histological examination of tumors. Nude mouse tumors in the untreated control group (A) and BPA-mediated BNCT in combination
with sonoporation group (B, C and D) were subjected to histological examinations. Twenty four hours after treatment, the vacuolation of tumor
cells, fragmentation of nuclei, enlarged and multinucleated cells were observed (B). Although vacuolation appeared in the dermis, cell layers in
the epidermis (arrow head) were preserved without degradation (C and D). Arrows showed the margin of the tumors produced by subcutaneous
inoculation of SAS cells (C).
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concentrations by sonoporation was 1.4-fold. Neverthe-
less, the growth of tumors was markedly suppressed,
and most tumors became undetectable 12 days after
neutron exposure. Although the amounts of BPA in the
tumors did not increase significantly, sonoporation may
affect the microlocalization of BPA in tumors and
promote the incorporation of BPA into each tumor cell.
This contributed to the enhancement in antitumor
ability of BPA-mediated BNCT. The BPA levels in qui-
escent tumor cells and low-LAT-expressing tumor cells
may be also improved by sonoporation. Regarding to
BSH, sonoporation did not enhance the antitumoral
effect of BNCT, probably, which may have been because
the concentration of 10B attained in tumors was very low.
Recent studies indicated that BSH could be a source for
novel forms of 10B compounds such as BSH-encapsulating
liposomes, and transferrin-conjugated polyethylenglycol
liposomes encapsulating BSH [28,29]. The effect of
sonoporation should be investigated using novel BSH
derivatives.
The area exposed to ultrasound was defined by the
diameter of the ultrasound transducer. We used a trans-
ducer 12 mm in diameter, which completely covered
tumor surface, and found a significant effect of BPA-mediated BNCT. An appropriate transducer should be
used to enhance the effect of BNCT and reduce damage
to the surrounding tissues. If sonoporation increased
the incorporation of BPA into the skin, BNCT may
affect its viability. However, no apparent skin damage
occurred at the site of sonoporation and cell layers of
the epidermis did not degrade histologically (Figures 3
and 4). The walls of tumor blood vessels were previously
shown to have widened interendothelial junctions and a
discontinuous or absent basement membrane, which
made tumor vessels leaky [30]. Although aberrant tumor
blood vessels allow BPA to reach each tumor cells, this
distribution of BPA does not occur in the normal epider-
mis. More importantly, the expression of LAT is increased
in many types of tumor cells [26]. In this situation, the
skin may avoid damage by BNCT, even when sonopora-
tion is applied.Conclusions
We demonstrated that sonoporation increased the incorp-
oration of BPA and BSH into oral SCC xenografts in nude
mice. The growth of tumors was more suppressed by
BPA-mediated BNCT in combination with sonoporation
than by BPA-mediated BNCT and the survival rate was
Yamatomo et al. Radiation Oncology 2013, 8:280 Page 7 of 7
http://www.ro-journal.com/content/8/1/280also prolonged. This method may be useful for enhancing
the antitumor effect of BPA-mediated BNCT.
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